The Comprehensive Role of High Mobility Group Box 1 (HMGB1) Protein in Different Tumors: A Pan-Cancer Analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021;18(10):663–672. doi:10.1038/s41571-021-00514-z
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Andersson U. Targeting Inflammation Driven by HMGB1. Front Immunol. 2020;11:484. doi:10.3389/fimmu.2020.00484
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195. doi:10.1038/nature00858
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045. doi:10.1146/annurev.iy.12.040194.005015
   PubMed Web of Science ®Google Scholar
• Thomas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans. 2001;29(Pt 4):395–401. doi:10.1042/bst0290395
   Google Scholar
• Yang H, Wang H, Ju Z, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015;212(1):5–14. doi:10.1084/jem.20141318
   PubMed Web of Science ®Google Scholar
• Grégoire M, Tadié JM, Uhel F, et al. Frontline science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. J Leukoc Biol. 2017;101(6):1281–1287. doi:10.1189/jlb.5HI0316-128RR
   Web of Science ®Google Scholar
• Spagnuolo L, Puddinu V, Boss N, et al. HMGB1 promotes CXCL12-dependent egress of murine B cells from Peyer’s patches in homeostasis. Eur J Immunol. 2021;51(8):1980–1991. doi:10.1002/eji.202049120
   Web of Science ®Google Scholar
• Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005;174(12):7506–7515. doi:10.4049/jimmunol.174.12.7506
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5(8):825–830. doi:10.1038/sj.embor.7400205
   PubMed Web of Science ®Google Scholar
• Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol. 2003;170(7):3890–3897. doi:10.4049/jimmunol.170.7.3890
   PubMed Web of Science ®Google Scholar
• Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–388. doi:10.1146/annurev.immunol.021908.132603
   PubMed Web of Science ®Google Scholar
• Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003;48(7):2052–2058. doi:10.1002/art.11161
   PubMed Web of Science ®Google Scholar
• Dupire G, Nicaise C, Gangji V, Soyfoo MS. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren’s syndrome. Scand J Rheumatol. 2012;41(2):120–123. doi:10.3109/03009742.2011.633099
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang Y. HMGB1 in inflammation and cancer. J Hematol Oncol. 2020;13(1):116. doi:10.1186/s13045-020-00950-x
   PubMed Web of Science ®Google Scholar
• Choi YR, Kim H, Kang HJ, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 2003;63(9):2188–2193.
   Web of Science ®Google Scholar
• Pusterla T, Nèmeth J, Stein I, et al. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 2013;58(1):363–373. doi:10.1002/hep.26395
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan W, Tohme S, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015;63(1):114–121. doi:10.1016/j.jhep.2015.02.009
   PubMed Web of Science ®Google Scholar
• Wu CZ, Zheng JJ, Bai YH, Xia P, Zhang HC, Guo Y. HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma. Onco Targets Ther. 2018;11:4501–4510. doi:10.2147/OTT.S167197
   PubMed Web of Science ®Google Scholar
• Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin. 2007;28(12):1957–1967. doi:10.1111/j.1745-7254.2007.00669.x
   Web of Science ®Google Scholar
• Cámara-Quílez M, Barreiro-Alonso A, Vizoso-Vázquez Á, et al. The HMGB1-2 ovarian cancer interactome. The role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response. Cancers. 2020;12(9):2435. doi:10.3390/cancers12092435
   Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Tu Z, Peng J, Long X, et al. Sperm autoantigenic protein 17 predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis. Front Immunol. 2022;13:844736. doi:10.3389/fimmu.2022.844736
   PubMedGoogle Scholar
• Zeng D, Li M, Zhou R, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7(5):737–750. doi:10.1158/2326-6066.CIR-18-0436
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:10.1200/PO.17.00073
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhang X, Zhu H, et al. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. Oncol Rep. 2021;45(2):523–534. doi:10.3892/or.2020.7890
   PubMed Web of Science ®Google Scholar
• Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 1973;38(1):14–19. doi:10.1111/j.1432-1033.1973.tb03026.x
   PubMedGoogle Scholar
• Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40:1–116. doi:10.1016/j.mam.2014.05.001
   PubMed Web of Science ®Google Scholar
• Rrapaj E, Trisolini E, Bertero L, et al. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma. Histopathology. 2018;72(6):1039–1050. doi:10.1111/his.13470
   Web of Science ®Google Scholar
• Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem. 1989;185(2):303–310. doi:10.1111/j.1432-1033.1989.tb15116.x
   PubMedGoogle Scholar
• Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17. doi:10.1186/1479-5876-7-17
   PubMed Web of Science ®Google Scholar
• Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13(10):2836–2848. doi:10.1158/1078-0432.CCR-06-1953
   PubMed Web of Science ®Google Scholar
• Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162. doi:10.1146/annurev-immunol-030409-101323
   PubMed Web of Science ®Google Scholar
• Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022;54(2):91–102. doi:10.1038/s12276-022-00736-w
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao ZH, Ding ST, Wu HH, Lu JJ. High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev. 2013;14(10):5789–5795. doi:10.7314/APJCP.2013.14.10.5789
   Google Scholar
• Chen G, Ward MF, Sama AE, Wang H. Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res. 2004;24(6):329–333. doi:10.1089/107999004323142187
   PubMed Web of Science ®Google Scholar
• Mandke P, Vasquez KM. Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: implications in DNA repair and immune responses. DNA Repair. 2019;83:102701. doi:10.1016/j.dnarep.2019.102701
   PubMed Web of Science ®Google Scholar
• Richard SA, Jiang Y, Xiang LH, et al. Post-translational modifications of high mobility group box 1 and cancer. Am J Transl Res. 2017;9(12):5181–5196.
   Web of Science ®Google Scholar
• Wang J, Li R, Peng Z, Hu B, Rao X, Li J. HMGB1 participates in LPS‑induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF‑κB signaling pathways. Int J Mol Med. 2020;45(1):61–80. doi:10.3892/ijmm.2019.4402
   PubMed Web of Science ®Google Scholar
• Pal Singh M, Pal Khaket T, Bajpai VK, et al. Morin hydrate sensitizes hepatoma cells and xenograft tumor towards cisplatin by downregulating PARP-1-HMGB1 mediated autophagy. Int J Mol Sci. 2020;21:21. doi:10.3390/ijms21218253
   Web of Science ®Google Scholar
• Tan G, Huang C, Chen J, Zhi F. HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway. J Hematol Oncol. 2020;13(1):149. doi:10.1186/s13045-020-00985-0
   PubMed Web of Science ®Google Scholar
• Zhu L, Ren S, Daniels MJ, et al. Exogenous HMGB1 promotes the proliferation and metastasis of pancreatic cancer cells. Front Med. 2021;8:756988. doi:10.3389/fmed.2021.756988
   Web of Science ®Google Scholar
• Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–68. doi:10.1016/j.canlet.2016.01.043
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol. 2020;11:2039. doi:10.3389/fimmu.2020.02039
   PubMed Web of Science ®Google Scholar
• van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86:102024. doi:10.1016/j.ctrv.2020.102024
   PubMed Web of Science ®Google Scholar
• Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012;49(3):151–157. doi:10.1136/jmedgenet-2011-100714
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang L, Jiang S, et al. HMGB1 mediates lipopolysaccharide-induced inflammation via interacting with GPX4 in colon cancer cells. Cancer Cell Int. 2020;20:205. doi:10.1186/s12935-020-01289-6
   PubMed Web of Science ®Google Scholar
• Cho K, Choi ES, Kim JH, Son JW, Kim E. Numerical learning of deep features from drug-exposed cell images to calculate IC50 without staining. Sci Rep. 2022;12(1):6610. doi:10.1038/s41598-022-10643-9
   Web of Science ®Google Scholar
• Weaver BA, Bement W. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677–2681. doi:10.1091/mbc.e14-04-0916
   PubMed Web of Science ®Google Scholar
• Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643–2655. doi:10.1200/JCO.1995.13.10.2643
   PubMed Web of Science ®Google Scholar
• Fluorouracil. Drugs and Lactation Database (Lactmed). Bethesda (MD): National Library of Medicine (US); 2006.
   Google Scholar
• Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. doi:10.1016/j.bioorg.2019.102925
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68(6):1014–1023. doi:10.1136/gutjnl-2017-315084
   PubMed Web of Science ®Google Scholar
• Yu S, Qian L, Ma J. Genetic alterations, RNA expression profiling and DNA methylation of HMGB1 in malignancies. J Cell Mol Med. 2022;26(15):4322–4332. doi:10.1111/jcmm.17454
   Web of Science ®Google Scholar
• Lin T, Zhang Y, Lin Z, Peng L. Roles of HMGBs in prognosis and immunotherapy: a pan-cancer analysis. Front Genet. 2021;12:764245. doi:10.3389/fgene.2021.764245
   Google Scholar